How Modified RNA Tricks Cells Into Making Proteins Without Triggering Attacks
A breakthrough method for using modified RNA to deliver instructions to cells without causing the body to reject the treatment as a foreign invader.
Patent Number
US 8278036
Status
Active
Filing Date
August 21, 2006
Grant Date
October 2, 2012
Expiration
August 21, 2026
Claims
22
Assignee
University of Pennsylvania Penn
Inventors
Drew Weissman, Katalin Kariko
Citations
322 forward · 3 backward
What it covers
This patent describes a way to make synthetic RNA molecules that look and act like natural RNA so the body's immune system doesn't attack them. By replacing the standard building block uridine with a modified version called pseudouridine, the RNA avoids triggering the cell's internal alarm systems, such as Toll-like receptors. This allows the cell to read the RNA instructions and produce a specific protein, like erythropoietin, without the cell shutting down or releasing inflammatory cytokines. The method includes synthesizing this RNA in a lab and delivering it to cells, often inside protective lipid nanoparticles.
What it doesn't cover
- —Does not cover naturally occurring RNA found in the body.
- —Does not cover unmodified RNA that triggers a standard immune response.
- —Does not cover DNA-based gene therapy or viral vector delivery systems that do not use the specified modified RNA.
- —Does not claim the specific protein being encoded, only the method of using modified RNA to induce its production.
The clever bit
The inventors realized that the immune system's hostility toward synthetic RNA wasn't a bug, but a feature—it was detecting the lack of specific chemical modifications found in natural RNA. By simply swapping one building block, they turned a 'foreign' signal into a 'self' signal.
Why it matters
This technology is the foundation for modern mRNA vaccines, including those used against COVID-19. Before this discovery by Katalin Kariko and Drew Weissman, synthetic RNA was largely ignored by the medical community because it was too inflammatory to be useful as a therapy. It effectively unlocked the potential of RNA as a programmable medicine.
Real-world examples
- 1.Pfizer-BioNTech COVID-19 vaccine
- 2.Moderna COVID-19 vaccine
- 3.Experimental mRNA cancer vaccines
Generated by PatentBrief · Not legal advice · patentbrief.org
US 8278036 · 2026